|Bid||2.0800 x 900|
|Ask||2.0500 x 1000|
|Day's Range||2.0201 - 2.1300|
|52 Week Range||0.8620 - 7.0700|
|Beta (5Y Monthly)||1.92|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The primary endpoint of the study was to determine the dosage regimen to be used in a proposed Phase II study of the safety and efficacy of MTX110 in patients with DIPG.
R&D; Collaboration Strategy Gaining TractionABINGDON, OXFORDSHIRE / ACCESSWIRE / September 10, 2020 / Midatech Pharma PLC (AIM:MTPH.
ABINGDON, OXFORDSHIRE / ACCESSWIRE / September 7, 2020 / Midatech Pharma PLC (AIM:MTPH.